Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Johannes R Bogner. (2012) Nevirapine extended-release for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy 10:1, pages 21-30.
Read now
Read now
Vanessa Cooper, GraemeJ. Moyle, Martin Fisher, Geraldine Reilly, Jacqueline Ewan, HuiC. Liu, Rob Horne & for the SWEET (Simplification With Easier Emtricitabine Tenofovir) group, UK. (2011) Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 23:6, pages 705-713.
Read now
Read now
Rosario Palacios, Isabel Aguilar, Ana Hidalgo & Jesús Santos. (2006) Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Expert Review of Anti-infective Therapy 4:6, pages 965-971.
Read now
Read now
Articles from other publishers (13)
Radko Avi, Merit Pauskar, Tõnis Karki, Eveli Kallas, Ene-Ly Jõgeda, Tõnu Margus, Kristi Huik & Irja Lutsar. (2016) Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology 88:3, pages 448-454.
Crossref
Crossref
Kit N Simpson, Kristin A Hanson, Gale Harding, Seema Haider, Margaret Tawadrous, Alexandra Khachatryan, Chris L Pashos & Albert W Wu. (2013) Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health and Quality of Life Outcomes 11:1.
Crossref
Crossref
S. Swaminathan, C. Padmapriyadarsini, P. Venkatesan, G. Narendran, S. Ramesh Kumar, S. Iliayas, P. A. Menon, S. Selvaraju, N. P. Pooranagangadevi, P. K. Bhavani, C. Ponnuraja, M. Dilip & R. Ramachandran. (2011) Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial. Clinical Infectious Diseases 53:7, pages 716-724.
Crossref
Crossref
Michael PfallerValérie Martinez & Jean-Michel Molina. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
2512
2532
.
Luciana Geocze, Samantha Mucci, Mario Alfredo De Marco, Luiz Antonio Nogueira-Martins & Vanessa de Albuquerque Citero. (2010) Qualidade de vida e adesão ao tratamento anti-retroviral de pacientes portadores de HIV. Revista de Saúde Pública 44:4, pages 743-749.
Crossref
Crossref
Vanessa Cooper, Rob Horne, Grace Gellaitry, Bernard Vrijens, Anne-Catherine Lange, Martin Fisher & David White. (2010) The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, pages 369-377.
Crossref
Crossref
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, pages 910-928.
Crossref
Crossref
Alejandro Arenas-Pinto. (2009) Safety and Efficacy of Didanosine Enteric-Coated Capsule in Patients with HIV-1 Infection. Clinical Medicine. Therapeutics 1, pages CMT.S3049.
Crossref
Crossref
M. Crespo, E. Ribera, I. Suarez-Lozano, P. Domingo, E. Pedrol, J. Lopez-Aldeguer, A. Munoz, C. Vilades, T. Sanchez, P. Viciana, R. Teira, M. L. Garcia-Alcalde, A. Vergara, F. Lozano, M. J. Galindo, J. Cosin, B. Roca, A. Terron, P. Geijo, F. Vidal & M. Garrido. (2008) Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. Journal of Antimicrobial Chemotherapy 63:1, pages 189-196.
Crossref
Crossref
Juan Berenguer, Juan González, Esteban Ribera, Pere Domingo, Jesús Santos, Pilar Miralles, Mª Angels Ribas, Víctor Asensi, Juan Luis Gimeno, José Antonio Pérez‐Molina, José Alberto Terrón, Juan Miguel Santamaría & Enric Pedrol. (2008) Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903. Clinical Infectious Diseases 47:8, pages 1083-1092.
Crossref
Crossref
S.I. Aquino-GarcíaM.A. RivasA. Ceballos-SalobreñaA.E. Acosta-GioL.A. Gaitán-Cepeda. (2008)
Short Communication:
Oral Lesions in HIV/AIDS Patients Undergoing HAART Including Efavirenz
. AIDS Research and Human Retroviruses 24:6, pages 815-820.
Crossref
Crossref
Jesús SantosRosario PalaciosFernando LozanoManuel LópezMaría Carmen GálvezJavier de la TorresLuis Fernando López-CortésMaría José RíosAntonio Rivero. (2008) Long-Term Assessment of Didanosine, Lamivudine, and Efavirenz in Antiretroviral-Naive Patients: 3-Year Follow-Up. AIDS Research and Human Retroviruses 24:1, pages 24-26.
Crossref
Crossref
Matilde Sánchez-CondeRosario PalaciosJosé SanzSonia Rodríguez-NovoaPablo RivasJesús SantosJulio SolaVictor AsensiCarmen de MendozaVicente EstradaPablo BarreiroJuan González-LahozInmaculada Jiménez-NacherVincent Soriano. (2007) Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. AIDS Research and Human Retroviruses 23:10, pages 1237-1241.
Crossref
Crossref